U.S. prescription drug prices see largest annual decline since 1963

U.S. prescription drug prices have experienced their largest annual decline since 1963. Recent data indicates a 3.1% to 3.9% year-over-year drop, alongside decreases in non-prescription drugs and medical equipment costs.

The Trump administration attributes this decline to the ‘Most Favored Nation’ policy, which aims to align U.S. drug prices with those of other developed nations, and the TrumpRx initiative. These measures have reportedly impacted the pricing of GLP-1 drugs, such as Ozempic and Wegovy, as well as insulin and cholesterol treatments.

However, drug pricing experts suggest the causes are multifaceted. Analysts point to the impact of generic and biosimilar competition, as well as legislation from the Biden administration that allows Medicare to negotiate drug prices. Additionally, experts note that the Labor Department’s price index measures pharmacy payments rather than direct consumer out-of-pocket costs, making it difficult to attribute the trend to a single policy.